In 2019, we saw significant developments in the prevention, diagnosis and treatment of HIV and hepatitis C. We helped launch a blueprint for hepatitis C elimination in Canada. We witnessed innovation in HIV prevention and testing approaches, more people cured of hepatitis C, and “the London patient”, the second person cleared of HIV after discontinuing antiretroviral therapy. We also saw drawbacks. We continue to confront a devastating opioid overdose crisis driven by a poisoned drug supply, which claimed the lives of more than 2,000 Canadians in the first six months of the year alone.